Castleman’s Disease Symptoms, Causes and Treatment News

What is Castleman’s Disease? (Definition)

(Symptoms, Causes & Treatment)

According to the Myeloma Institute, Castleman disease (CD) is a rare disease of lymph nodes and related tissues that results from the overgrowth of the cells located in the lymphatic system of the body. Although Castleman Disease is not considered a cancer, it can develop into lymphoma. There are two main types of Castleman Disease: Unicentric, which is localized and affects only a single lymph node region, and Multicentric, which is widespread and affects multiple lymph nodes and lymphatic tissues and which can severely weaken the immune system. Multicentric Castleman Disease can be further classified as either HHH-8 -positive or HHV-8-negative.



See below for updated news and information regarding Castleman’s Disease including new medical research, treatment options and advancements. 

Latest Castleman’s Disease Research – Treatment News, Discoveries and Findings

No recent news regarding Castleman’s Disease is available. 

Support Organizations

Myeloma Institute

Clinical Resources: Treatment Therapies & Guidelines

healthcare careers

science careers

Clinical Trials – Investigational Therapies

For information on current clinical trials, visit This is a searchable registry and results database of federally and privately supported clinical trials taking place in the U.S and abroad. provides information about a trial’s purpose, who may participate, locations, and phone numbers. This information should be used in conjunction with advice from health care professionals.

For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll Free: (800) 411-1222
TTY: (866) 411-1010

For information about clinical trials conducted in Europe, visit:

If you have experience dealing with this disease or condition (especially with regard to symptoms, diagnosis, causes or treatment), please share below: